Rockwell Medical, Inc. (NASDAQ:RMTI) Q2 2023 Earnings Call Transcript

Operator: [Operator Instructions] And there are no further questions at this time. I will now turn the call back over to Dr. Strobeck for some final closing remarks.

Mark Strobeck: Thank you, everyone, for joining us on today’s call. Before we conclude our call, I’d like to take a moment and say thank you to a few key members of the Evoqua team who were instrumental in supporting Rockwell’s acquisition of this hemodialysis concentrates business. Doug McFarland and Beth Huddleston, over my 20-year career, I have completed many transactions and partnering with Doug and Beth to complete this acquisition has been one of the most productive experiences to-date. Their professionalism, experience, understanding and balance makes them among the best in this business. On behalf of the entire team at Rockwell, I want to take a moment and thank them for their hard work to complete this transaction.

We look forward to partnering with them through this transition and wish them continued success under their new structure with Xylem. We have accomplished a lot in the last year, but there is more work ahead for us. While a lot of this discussion has been focused on top and bottom line revenue, profitability improved margins et cetera. All of this is being done with the sole purpose of ensuring the longevity of our business to support clinics and the patients they serve for years to come. Thank you to all of our employees for all their hard work and continued dedication and to our shareholders for their continued support. I look forward to sharing our progress on future calls as we continue to work diligently to unlock the value of Rockwell.

Operator: This concludes today’s conference call and webcast. You may now disconnect.